Einzelfraktionierte stereotaktische Radiochirurgie im Vergleich mit fraktionierter stereotaktischer Radiochirurgie zur Behandlung von intakten metastasierten Hirnerkrankungen, FRACTIONATE Trial
Phase-IIR-Studie zur stereotaktischen Einzelfraktions-Radiochirurgie (SRS) im Vergleich zu fraktionierter SRS (FSRS) bei intakter metastasierter Hirnerkrankung (FRACTIONATE)
This phase II trial compares the effect of single fraction stereotactic radiosurgery to fractionated stereotactic radiosurgery for the treatment of patients with cancer that has spread to the brain (metastatic brain disease). Stereotactic radiosurgery (SRS) is a form of radiation therapy that focuses high-power energy on a small area of the body. This trial is being done to determine if single (one) fraction stereotactic radiosurgery is better than fractionated stereotactic radiosurgery or vice versa in controlling tumor and side effects in patients with tumors that have spread to the brain.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. To ascertain if the composite endpoint of cumulative treatment failure, defined by time to either local failure or symptomatic radiation brain necrosis of the largest brain metastasis (target lesion), is increased with fractionated stereotactic radiosurgery (FSRS) compared to single fraction stereotactic radiosurgery (SSRS).
SECONDARY OBJECTIVES:
I. To ascertain whether there is improved overall survival in patients who undergo FSRS compared to patients who receive SSRS.
II. To tabulate and descriptively compare the post-treatment adverse events associated with the interventions, including the potential impact of immunotherapy and targeted therapy.
III. To compare rates of radiation necrosis in patients who receive FSRS to patients who receive SSRS.
IV. To evaluate if there is any difference in central nervous system (CNS) failure patterns (e.g. local, distant brain failure) in patients who receive FSRS compared to patients who receive SSRS.
V. To ascertain whether FSRS prolongs time to neurologic death as compared to SRS.
VI. To determine whether there is improved patient reported outcomes (Functional Assessment of Cancer Therapy [FACT]-Brain Symptom Index [FBrSI]-24) including quality of life for patients who receive FSRS compared to patients who receive SSRS.
VII. To evaluate if there is any difference in CNS failure patterns (e.g. local, distant brain failure) and symptomatic radiation necrosis rates in patients who are treated with gamma knife compared to patients who are treated with a linear accelerator platform.
VIII. To determine whether differences in time to local failure, time to necrosis, or their composite endpoint cumulative treatment failure differs between treatment arms (or other patient or treatment factors) when analyzed on a "per lesion" basis rather than the per patient basis utilized for the primary endpoint.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients undergo single fraction SRS. Patients also undergo magnetic resonance imaging (MRI) at screening and during follow up.
ARM B: Patients undergo fractionated SRS, for 3-5 treatments, given over no more than 8 days. Patients also undergo MRI at screening and during follow up.
After completion of study treatment, patients are followed up at 3 months, every 3 months for 2 years, and then every 6 months for 3 years.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-Mail: mayocliniccancerstudies@mayo.edu
Studienorte
-
-
Arizona
-
Scottsdale, Arizona, Vereinigte Staaten, 85259
- Rekrutierung
- Mayo Clinic in Arizona
-
Kontakt:
- Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-Mail: mayocliniccancerstudies@mayo.edu
-
Hauptermittler:
- Sujay A. Vora, MD
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32224
- Rekrutierung
- Mayo Clinic in Florida
-
Kontakt:
- Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-Mail: mayocliniccancerstudies@mayo.edu
-
Hauptermittler:
- Jennifer L. Peterson, MD
-
-
Minnesota
-
Albert Lea, Minnesota, Vereinigte Staaten, 56007
- Noch keine Rekrutierung
- Mayo Clinic Health System in Albert Lea
-
Kontakt:
- Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-Mail: mayocliniccancerstudies@mayo.edu
-
Hauptermittler:
- John Yeakel, MD
-
Kontakt:
- Lori Rhodes
- Telefonnummer: 507-284-0063
- E-Mail: Rhodes.Lori@mayo.edu
-
Mankato, Minnesota, Vereinigte Staaten, 56001
- Rekrutierung
- Mayo Clinic Health Systems-Mankato
-
Kontakt:
- Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-Mail: mayocliniccancerstudies@mayo.edu
-
Kontakt:
- Lori Rhodes
- Telefonnummer: 507-284-0063
- E-Mail: Rhodes.Lori@mayo.edu
-
Hauptermittler:
- Jason T. Hayes, MD
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Rekrutierung
- Mayo Clinic in Rochester
-
Hauptermittler:
- Paul D. Brown, M.D.
-
Kontakt:
- Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-Mail: mayocliniccancerstudies@mayo.edu
-
-
Wisconsin
-
Eau Claire, Wisconsin, Vereinigte Staaten, 54701
- Rekrutierung
- Mayo Clinic Health System-Eau Claire Clinic
-
Kontakt:
- Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-Mail: mayocliniccancerstudies@mayo.edu
-
Hauptermittler:
- Now Bahar Alam, MD
-
Kontakt:
- Lori Rhodes
- Telefonnummer: 507-284-0063
- E-Mail: Rhodes.Lori@mayo.edu
-
La Crosse, Wisconsin, Vereinigte Staaten, 54601
- Rekrutierung
- Mayo Clinic Health System-Franciscan Healthcare
-
Kontakt:
- Clinical Trials Referral Office
- Telefonnummer: 855-776-0015
- E-Mail: mayocliniccancerstudies@mayo.edu
-
Hauptermittler:
- Abigail L. Stockham, MD
-
Kontakt:
- Lori Rhodes
- Telefonnummer: 507-284-0063
- E-Mail: Rhodes.Lori@mayo.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Age >= 18 years old
-
Presence of presumed brain metastases from an extra-cerebral tumor site (e.g. lung, breast, prostate, etc.)
- Note: Dural based metastases (e.g. commonly seen in breast cancer) are eligible
-
Size of brain metastases
- At least one intact metastasis (not previously treated with radiosurgery) must measure >= 2.0 cm and =< 4.0 cm in maximal extent on the contrasted pre-treatment magnetic resonance imaging (MRI) brain scan obtained =< 28 days prior to registration
- If the largest lesion measures >= 2.0 to =< 4.0 cm in maximal extent the patient will be randomized
-
Able to undergo contrast enhanced MRI brain
-
Negative urine or serum pregnancy test completed =< 7 days prior to registration, for women of childbearing potential only
-
Patient is willing and able to provide written informed consent or have a legally Authorized Representative (LAR) who is responsible for the care and well-being of the potential study participant provide consent.
-
Karnofsky performance status (KPS) >= 50
-
Eastern Cooperative Oncology Group (ECOG) performance score of (PS) >= 2
-
Past radiosurgery or resection is allowed as long as no definitive evidence of progression in these locations
- Note: Repeat radiosurgery to the same location/lesion is not allowed on this protocol
Exclusion Criteria:
-
Any patient who has received previous whole brain radiation
-
Any brain metastasis that is located in the brainstem measuring >= 2.0 cm in maximal extent
-
Any patient with definitive evidence of leptomeningeal metastasis (LMD)
- NOTE: For the purposes of exclusion, LMD is a clinical diagnosis, defined as positive cerebrospinal fluid (CSF) cytology and/or unequivocal radiologic or clinical evidence of leptomeningeal involvement. Patients with leptomeningeal symptoms in the setting of leptomeningeal enhancement by imaging (MRI) would be considered to have LMD even in the absence of positive CSF cytology, unless a parenchymal lesion can adequately explain the neurologic symptoms and/or signs. In contrast, an asymptomatic or minimally symptomatic patient with mild or nonspecific leptomeningeal enhancement (MRI) would not be considered to have LMD. In that patient, CSF sampling is not required to formally exclude LMD, but can be performed at the investigator's discretion based on level of clinical suspicion
-
Any patient with an intact brain metastasis measuring > 4.0 cm
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Sonstiges: Arm A (single fraction SRS)
Patients undergo single fraction SRS. Patients also undergo MRI at screening and during follow up. |
Undergo MRI
Andere Namen:
Ancillary studies Undergo single fraction SRS
Andere Namen:
Undergo fractionated SRS
Andere Namen:
|
|
Sonstiges: Arm B (fractionated SRS)
Patients undergo fractionated SRS, for 3-5 treatments, given over no more than 8 days.. Patients also undergo MRI at screening and during follow up. |
Undergo MRI
Andere Namen:
Ancillary studies Undergo single fraction SRS
Andere Namen:
Undergo fractionated SRS
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time to local failure or symptomatic radiation brain necrosis of large brain metastasis
Zeitfenster: Up to 5 years
|
Will determine if the composite endpoint of time to local failure or symptomatic radiation brain necrosis of a large brain metastasis [cumulative treatment failure (CTF)] is increased with fractionated stereotactic radiosurgery (FSRS) compared to single fraction stereotactic radiosurgery (SSRS). |
Up to 5 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall survival (OS)
Zeitfenster: From study entry to death from any cause, assessed up to 5 years
|
OS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. Medians and 95% confidence intervals will be reported. |
From study entry to death from any cause, assessed up to 5 years
|
|
Incidence of adverse events
Zeitfenster: Up to 2 years post radiation therapy
|
The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test. |
Up to 2 years post radiation therapy
|
|
Rates of radiation necrosis
Zeitfenster: Up to 5 years
|
Will compare rates of radiation necrosis in patients who receive FSRS to patients who receive SSRS. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test. |
Up to 5 years
|
|
Central nervous system (CNS) failure patterns (Fractionation)
Zeitfenster: Up to 5 years
|
Will evaluate if there is any difference in CNS failure patterns (e.g. local, distant brain failure) in patients who receive FSRS compared to patients who receive SSRS. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test. |
Up to 5 years
|
|
Time to neurologic death
Zeitfenster: Up to 5 years
|
Will ascertain whether FSRS prolongs time to neurologic death as compared to SSRS. This will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. Medians and 95% confidence intervals will be reported. |
Up to 5 years
|
|
Quality of life (QOL)
Zeitfenster: Up to 5 years
|
Will determine whether there are improved patient reported outcomes (Functional Assessment of Cancer Therapy [FACT]-Brain Symptom Index [FBrSI]-24) including quality of life for patients who receive FSRS compared to patients who receive SSRS. Changes over time in QOL from baseline will be compared between arms using the 2-sample t-test (or Wilcoxon Rank-Sum test for non-normal data). Box-plots will be used to show differences between arms graphically. |
Up to 5 years
|
|
CNS failure patterns (Gamma Knife)
Zeitfenster: Up to 5 years
|
Will evaluate if there is any difference in CNS failure patterns (e.g. local, distant brain failure) and symptomatic radiation necrosis rates in patients who are treated with Gamma Knife compared to patients who are treated with a linear accelerator platform. Comparisons between arms will be made by using either the Chi-square or Fisher's Exact test. |
Up to 5 years
|
|
Per lesion analysis between treatment arms: time to local failure
Zeitfenster: Up to 5 years
|
Will determine whether differences in time to local failure differs between treatment arms (or other patient or treatment factors) when analyzed on a "per lesion" basis rather than the per patient basis utilized for the primary endpoint. Time-to-event models (Cox and Kaplan- Meier) with sandwich estimators for covariance will be utilized to in treatment comparisons, with model comparisons completed through log-likelihood and Akaike Information Criterion. |
Up to 5 years
|
|
Per lesion analysis between treatment arms: time to necrosis
Zeitfenster: Up to 5 years
|
Will determine whether differences in time to necrosis differs between treatment arms (or other patient or treatment factors) when analyzed on a "per lesion" basis rather than the per patient basis utilized for the primary endpoint. Time-to-event models (Cox and Kaplan- Meier) with sandwich estimators for covariance will be utilized to in treatment comparisons, with model comparisons completed through log-likelihood and Akaike Information Criterion. |
Up to 5 years
|
|
Per lesion analysis between treatment arms: endpoint CTF
Zeitfenster: Up to 5 years
|
Will determine whether differences in the composite endpoint CTF differs between treatment arms (or other patient or treatment factors) when analyzed on a "per lesion" basis rather than the per patient basis utilized for the primary endpoint. Time-to-event models (Cox and Kaplan- Meier) with sandwich estimators for covariance will be utilized to in treatment comparisons, with model comparisons completed through log-likelihood and Akaike Information Criterion. |
Up to 5 years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Paul D. Brown, MD, Mayo Clinic in Rochester
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Pathologische Prozesse
- Neubildungen nach Standort
- Neubildungen
- Neoplastische Prozesse
- Neubildungen des Nervensystems
- Neubildungen des zentralen Nervensystems
- Pathologische Zustände, Anzeichen und Symptome
- Neoplasma Metastasierung
- Neubildungen des Gehirns
- Untersuchungstechniken
- Therapeutika
- Chirurgische Eingriffe, operativ
- Physikalische Phänomene
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Elektromagnetische Phänomene
- Magnetische Phänomene
- Strahlentherapie
- Stereotaktische Techniken
- Neurochirurgische Verfahren
- Elektromagnetische Strahlung
- Strahlung
- Strahlung, ionisieren
- Magnetresonanzspektroskopie
- Radiochirurgie
- Röntgenaufnahmen
Andere Studien-ID-Nummern
- GMROR2163
- NCI-2021-14230 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- 21-003768 (Andere Kennung: Mayo Clinic Institutional Review Board)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .